Updated
Clinuvel PharmaceuticalsCUVL · Healthcare
$5.16-0.39%
Market cap$260M
IndustryBiotechnology
Clinuvel Pharmaceuticals (CUVL) Revenue breakdown
By product, Commercial Sales of Goods is the largest at 90% of fiscal 2026 revenue; Sales Under Special Access Reimbursement Programs grew fastest, 19% a year over 2 years.
Summary
By region, Ireland is the largest at 56% of fiscal 2026 revenue, growing 10% a year over 2 years.
Revenue by product
Fiscal years, as Clinuvel Pharmaceuticals reports them in its 10-K filings; fiscal 2026 total $64M.
| Products | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|
| Commercial Sales of Goods | $53M | $56M | $58M | 90% |
| Sales Under Special Access Reimbursement Programs | $5M | $6M | $6M | 10% |
Revenue by region
Fiscal years, as Clinuvel Pharmaceuticals reports them in its 10-K filings; fiscal 2026 total $64M.
| Regions | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|
| Ireland | $30M | $30M | $36M | 56% |
| United States | $28M | $31M | $28M | 43% |
| Rest of World | $519,344 | $584,297 | $553,112 | 1% |
Questions about Clinuvel Pharmaceuticals
Where does Clinuvel Pharmaceuticals make its money?
In fiscal 2026, by product: Commercial Sales of Goods $58M, Sales Under Special Access Reimbursement Programs $6M.
From Clinuvel Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.